Physician profile
Monica M Scheel
NPI 1568592772
$253,325.82
in general payments reported to CMS, 2019-2025
18 companies · $21K in 2025
The $21K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $6,815 · 2021: $29K · 2022: $58K · 2023: $74K · 2024: $49K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $116K · Consulting Fee: $12K · Travel and Lodging: $11K · Food and Beverage: $5,855 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $115,650.00 |
| Consulting Fee | $12,000.00 |
| Travel and Lodging | $10,618.51 |
| Food and Beverage | $5,855.30 |
| Education | $288.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $92,739.12 | 2019-2025 | Botox, Kybella, Rinvoq |
| Galderma Laboratories, L.P. | $81,300.31 | 2019-2025 | Dysport |
| Allergan, INC. | $62,371.88 | 2019-2022 | |
| Merz North America, INC. | $16,039.30 | 2022-2025 | Xeomin |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $231.71 | 2019-2022 | |
| Lilly USA, LLC | $126.00 | 2019-2024 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $96.37 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $78.08 | 2023-2024 | Zoryve |
| Celgene Corporation | $65.10 | 2019 | |
| Pfizer INC. | $57.95 | 2023 | |
| Genzyme Corporation | $46.00 | 2021-2024 | |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Incyte Corporation | $24.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.84 | 2022 | |
| Amgen INC. | $23.49 | 2025 | Otezla |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $21.32 | 2020 | |
| Leo Pharma INC. | $20.97 | 2024 | Adbry |
| Revance Therapeutics, INC. | $14.58 | 2025 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Scheel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.